Researchers discovered that even though cancer cells mutate wildly within a person's body, the cancer cells within each patient also have common mutations -- ones that could be isolated and fought off by certain immune cells.
As tumors grow they acquire mutations, some of which create neoantigens that influence the response of patients to immune checkpoint inhibitors. We explored the impact of neoantigen intra-tumor heterogeneity (ITH) on anti-tumor immunity....
These data suggest that neoantigen heterogeneity may influence immune surveillance and support therapeutic developments targeting clonal neoantigens.
